Tony Mire-Sluis, AstraZeneca; Chair, IABS Human Therapeutics Committee

Eytan Abraham, Lonza, Walkersville, Maryland

Yves Aubin, Health Canada, Ottawa, Ontario

Jeff Baker, FDA

Len Blackwell, Biogen, Raleigh-Durham, North Carolina

Steve Bowen, FDA/CDER

Vinny Browning, Amgen, Thousand Oaks, California

Janet Cheetham, Allotrope Foundation, Washington, D.C.

Barry Cherney, Amgen, Washington, D.C.

Merry Christie, FDA/ CDER

Ivar Kljavin, Genentech, a member of the Roche Group, San Francisco, California

Prakash Koodathingal, GlaxoSmithKline, Rockville, Maryland

Yun Liu, University of Delaware, Newark, Delaware

Joe Loo, UCLA and the Consortium for Top-Down Proteomics, California

John Marino, National Institute of Standards and Technology (NIST), Gaithersburg, Maryland

Ingrid Markovic, FDA/CDER

Christopher Middleton, PhaseTech Spectroscopy, Wisconsin

Ken Miller, MedImmune, Baltimore, Maryland

Jingjie Mo, Janssen R&D (Johnson and Johnson), Philadelphia, Pennsylvania

Jack Price, NIBSC, United Kingdom

Rajeev Ram, Massachusetts Institute of Technology, Cambridge, Massachusetts

Rob Reed, Postnova Analytics Inc, Salt Lake City, Utah

Oscar Salas-Solano, Seattle Genetics, Bothell, Washington

John Schiel, NIST, Gaithersburg, Maryland

Gopi Shankar, Janssen Research & Development, LLC (JNJ),Philadelphia, Pennsylvania

Tam Soden, Kite, a Gilead Company, Santa Monica, California

John Stults, Genentech, a Member of the Roche Group, San Francisco, California

Sriram Subramanian, NIH, Bethesda, Maryland

Frances Terry, EpiVax, Providence, Rhode Island

Valerie Tsang, Biogen, Raleigh-Durham, North Carolina